1. Home
  2. THM vs NMRA Comparison

THM vs NMRA Comparison

Compare THM & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Tower Hill Mines Ltd. (Canada)

THM

International Tower Hill Mines Ltd. (Canada)

HOLD

Current Price

$2.52

Market Cap

685.5M

Sector

N/A

ML Signal

HOLD

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$2.24

Market Cap

554.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
THM
NMRA
Founded
1978
2019
Country
Canada
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
685.5M
554.0M
IPO Year
2002
2023

Fundamental Metrics

Financial Performance
Metric
THM
NMRA
Price
$2.52
$2.24
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$7.50
AVG Volume (30 Days)
988.0K
1.4M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.63
52 Week High
$3.65
$3.65

Technical Indicators

Market Signals
Indicator
THM
NMRA
Relative Strength Index (RSI) 50.56 46.79
Support Level $2.17 $1.79
Resistance Level $3.63 $2.58
Average True Range (ATR) 0.15 0.17
MACD 0.02 0.05
Stochastic Oscillator 50.96 55.00

Price Performance

Historical Comparison
THM
NMRA

About THM International Tower Hill Mines Ltd. (Canada)

International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: